Portfolio – Open Trials

A randomised clinical trial testing a 1-week schedule of curative simultaneous integrated boost
radiotherapy against a standard 3-week schedule in patients with early breast cancer

A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors

The HER2-RADiCAL study (Response ADaptive CAre pLan) – Tailoring treatment for HER2 positive early breast cancer

Investigation of Circulating Haematological Biomarkers in Cancer

A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects with
Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

The interNational Anaplastic Thyroid Cancer Tissue Bank and Database Project

Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain

A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha as first line ThErapy for high risk polycythemia vera

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Optimising Therapy in FLT3-mutated Acute Myeloid Leukaemia

A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nabpaclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non small Cell Lung Cancer

Power of liquid biopsy tracking in immunotherapy treated stage IV melanoma

Prospective Observational Study Of Treatment And Outcomes For Patients With Newly Diagnosed Follicular Lymphoma

A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition with or without anti-PD-L1 immunotherapy in patients with neoadjuvant treatment resistant residual triple negative breast cancer

A Multicentre Open Label Randomised Phase III Trial Comparing Extended Nodal Irradiation with Stereotactic Body Radiotherapy for oligo-recurrent pelvic nodal prostate cancer